

PerCP/Cy5.5 anti-mouse H-2Kd

Catalog # / Size: 1183090 / 100 µg
1183085 / 25 µg

Clone: SF1-1.1

Isotype: Mouse IgG2a, κ


Immunogen: BALB/c Mouse cells

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.2



Balb/c mouse splenocytes stained with SF1-1.1 PerCP/Cy5.5

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.
* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes: The SF1-1.1 antibody is weakly cross-reactive with H-2k but does not cross-react with other haplotypes (b, j, p, q, s, v). Clone SF1-1.1 recognizes the α3 domain of Kd.

Additional reported applications (for the relevant formats) include: immunoprecipitation^{1,4} and Western blotting².

Application References:

1. Noun G, *et al.* 1996. *J. Immunol.* 157:2455. (IP)
2. Abasto JP, *et al.* 1993. *J. Immunol.* 151:3569. (WB)
3. Bashuda H, *et al.* 1997. *Transplantation* 63:113.
4. Sester M, *et al.* 2000. *J. Biol. Chem.* 34:113. (IP)
5. Ma XT, *et al.* 2006. *Cancer Res.* 66:1169. (FC)
6. Norian LA and Allen PM. 2004. *J. Immunol.* 173:835. (FC)
7. Norian L, *et al.* 2004. *J. Immunol.* 173:835. [PubMed](#)
8. Delon J, *et al.* 1998. *Immunity* 9:467.

Description: The SF1-1.1 antibody reacts with the H-2Kd MHC class I alloantigens expressed on nucleated cells from mice of the H-2Kd haplotype. H-2Kd is involved in antigen presentation to T cells expressing CD3/TCR and CD8 proteins.

Antigen References:

1. Watts C. 1997. *Annu. Rev. Immunol.* 15:821.
2. Pamer E, *et al.* 1998. *Annu. Rev. Immunol.* 16:323.
3. York I, *et al.* 1996. *Annu. Rev. Immunol.* 14:369.